Overview
Two Different Regimens of Bemiparin as a Thromboprophylaxis in Morbidly Obese Surgical Patients
Status:
Not yet recruiting
Not yet recruiting
Trial end date:
2025-04-02
2025-04-02
Target enrollment:
0
0
Participant gender:
All
All
Summary
Morbid obesity, is known to be associated with a high risk of VTE and, unfortunately, fixed doses of anticoagulant regimens may not provide optimal VTE prophylaxis in these patients especially after surgery.Phase:
N/AAccepts Healthy Volunteers?
Accepts Healthy VolunteersDetails
Lead Sponsor:
Hawler Medical UniversityTreatments:
Bemiparin
Heparin, Low-Molecular-Weight
Criteria
Inclusion Criteria:1. Participants required surgical intervention in: general surgery, orthopedic,
neurosurgery, gynecology, bariatric surgery
2. Moderate, high, and very high risk for venous thromboembolism according to Caprin RAM
3. Participant is willing and able to give informed consent for participation in the
study.
4. BMI ≥40kg/m2
Exclusion Criteria:
1. Having any contraindication to LMWH, such as active bleeding, history of
heparin-induced thrombocytopenia , baseline platelet count <75 × 108/μl, severe renal
disease (glomerular filtration rate <30 ml/minute), severe liver disease, or
uncontrolled hypertension (>200/120 mmHg)
2. Known hypersensitivity to unfractionated or LMWHs
3. On oral or parenteral anticoagulants within 5 days before surgery
4. Severe arterial hypertension
5. Unable to comply with the study treatment and/or follow-up
6. Receiving prohibited medications
7. Pregnancy or lactation mother